Multiplex Immunofluorescence Captures Progressive Immune Exhaustion with Advancing Penile Squamous Cell Cancer Stage

Penile squamous cell carcinoma (PSCC) is a rare and deadly malignancy. Therapeutic advances have been stifled by a poor understanding of disease biology. Specifically, the immune microenvironment is an underexplored component in PSCC and the activity of immune checkpoint inhibitors observed in a sub...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancers 2024-01, Vol.16 (2), p.303
Hauptverfasser: Ionescu, Filip, Nguyen, Jonathan, Segura, Carlos Moran, Paravathaneni, Mahati, Grass, G Daniel, Johnstone, Peter, Zacharias, Niki M, Pettaway, Curtis A, Lu, Xin, Kim, Youngchul, Whiting, Junmin, Dhillon, Jasreman, Eschrich, Steven A, Chadha, Juskaran, Gullapalli, Keerthi, Roman Souza, Gabriel, Miyagi, Hiroko, Manley, Brandon J, Spiess, Philippe E, Chahoud, Jad
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Penile squamous cell carcinoma (PSCC) is a rare and deadly malignancy. Therapeutic advances have been stifled by a poor understanding of disease biology. Specifically, the immune microenvironment is an underexplored component in PSCC and the activity of immune checkpoint inhibitors observed in a subset of patients suggests immune escape may play an important role in tumorigenesis. Herein, we explored for the first time the immune microenvironment of 57 men with PSCC and how it varies with the presence of human papillomavirus (HPV) infection and across tumor stages using multiplex immunofluorescence of key immune cell markers. We observed an increase in the density of immune effector cells in node-negative tumors and a progressive rise in inhibitory immune players such as type 2 macrophages and upregulation of the PD-L1 checkpoint in men with N1 and N2-3 disease. There were no differences in immune cell densities with HPV status.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers16020303